NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $6.23 -0.45 (-6.74%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$6.22 -0.02 (-0.24%) As of 11/20/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About SOPHiA GENETICS Stock (NASDAQ:SOPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$6.16▼$6.8850-Day Range$6.23▼$8.5352-Week Range$3.91▼$8.98Volume827,712 shsAverage Volume723,153 shsMarket Capitalization$522.67 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets. Founded in 2011 and headquartered in Rolle, Switzerland, SOPHiA GENETICS was co-founded by Jurgi Camblong, who has served as its chief executive officer.AI Generated. May Contain Errors. Read More SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreSOPH MarketRank™: 2.53574432296 of 5 starsSOPHiA GENETICS scored higher than 51% of companies evaluated by MarketBeat, and ranked 469th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingSOPHiA GENETICS has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSOPHiA GENETICS has a consensus price target of $10.00, representing about 60.5% upside from its current price of $6.23.Amount of Analyst CoverageSOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.94) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -5.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 7.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.44% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 14.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.34 News SentimentSOPHiA GENETICS has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added SOPHiA GENETICS to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,199,254.00 in company stock.Percentage Held by Insiders4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by Institutions31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SOPH Stock News HeadlinesSOPHiA: 3 Key Takeaways for Long-Term InvestorsNovember 16, 2026 | fool.comSOPHiA GENETICS Earnings Call Signals Strong MomentumNovember 14, 2026 | tipranks.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 22 at 1:00 AM | Base Camp Trading (Ad)Transcript : SOPHiA GENETICS SA Presents at 2026 UBS Global Healthcare Conference, Nov-09-2026 10:15 AMNovember 9, 2026 | marketscreener.comMSOPHiA GENETICS SA (SOPH) Presents at 2026 UBS Global Healthcare Conference TranscriptNovember 9, 2026 | seekingalpha.comSOPHiA GENETICS SA 2026 Q3 - Results - Earnings Call PresentationNovember 7, 2026 | seekingalpha.comSophia Genetics Sa Revises Earnings Guidance for the Full Year 2026November 4, 2026 | marketscreener.comMTranscript : SOPHiA GENETICS SA, Q3 2026 Earnings Call, Nov 03, 2026November 3, 2026 | marketscreener.comMSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $4.67 at the beginning of the year. Since then, SOPH stock has increased by 33.4% and is now trading at $6.23. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) issued its earnings results on Tuesday, November, 3rd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.04. The business earned $24.27 million during the quarter, compared to analyst estimates of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative trailing twelve-month return on equity of 128.69%. Read the conference call transcript. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering on Wednesday, July 21st 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? Top institutional shareholders of SOPHiA GENETICS include Royce & Associates LP (4.63%), AWM Investment Company Inc. (2.10%), AIGH Capital Management LLC (2.01%) and Marshall Wace LLP (0.47%). Insiders that own company stock include Jurgi Camblong, Ross Muken, Zhenyu Xu, Well Daan Van, George Cardoza, Manuela Valente, Philippe Menu, Abhimanyu Verma, Kevin Puylaert and Kathy L Hibbs. View institutional ownership trends. How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include NVIDIA (NVDA), Super Micro Computer (SMCI), Caribou Biosciences (CRBU), Micron Technology (MU), Advanced Micro Devices (AMD), Marvell Technology (MRVL) and Tesla (TSLA). Company Calendar Last Earnings11/03/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SOPH's financial health is in the Green zone, according to TradeSmith. SOPH has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees415Year Founded2011Price Target and Rating Average Price Target for SOPHiA GENETICS$10.00 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+60.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79 million Net Margins-89.18% Pretax Margin-88.90% Return on Equity-128.69% Return on Assets-44.73% Debt Debt-to-Equity Ratio0.70 Current Ratio2.29 Quick Ratio2.16 Sales & Book Value Annual Sales$90.97 million Price / Sales5.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book7.60Miscellaneous Outstanding Shares83,895,000Free Float79,801,000Market Cap$522.67 million OptionableOptionable Beta1.09 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:SOPH) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.